As predicted, it was a rough day for Idenix Pharma (IDIX -30.7%) following the FDA's request for...

As predicted, it was a rough day for Idenix Pharma (IDIX -30.7%) following the FDA's request for more info before its Hep C drug trials can proceed. The company had just begun in the last month to recover from a similar FDA intervention last year, in what Stephen Simpson called "the high-stakes ping-pong of Hep C treatments."

Comments (1)
  • 48870
    , contributor
    Comment (1) | Send Message
    In part, I can understand the stop (safety comes first) exercised by the FDA for the new trial, on the other hand, I wonder if there is not a well-designed conspiracy ( done by big giants via lobbying). To me, there is someone (even in the FDA ) which has the interest of blocking any improvement in this area made by this company ( in this case IDIX ). Do you think this is not corruption? Lobbying and corruption go hand in hand especially in this field, where the FDA are blocking a flood of natural products that help to heal without these high costs. The only thing is, no one has the courage to admit that there is a direct (hidden) link between the FDA, the pharmaceutical industry in general and politicians. Wins, the player who pays the most ! For this devious reason, I stopped taking any medicines marketed by pharmaceutical companies. With natural products (and out there, You can find a lot) I get very better results, cheaper and safer. No one should expect any response of the FDA, concerning the product locked (IDX184). If any answer, it will come when it's to late for IDINIX. That's the vicious game. Good luck to the transparency !
    22 Jun 2013, 04:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs